| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Hosalli, J M Davi. Depot risperidone for schizophrenia. The Cochrane database of systematic reviews. issue 4. 2004-05-04. PMID:14584007. |
depot risperidone for schizophrenia. |
2004-05-04 |
2023-08-12 |
Not clear |
| Philip D Harvey, Herbert Meltzer, George M Simpson, Steven G Potkin, Antony Loebel, Cynthia Siu, Steven J Roman. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia research. vol 66. issue 2-3. 2004-05-04. PMID:15061242. |
improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. |
2004-05-04 |
2023-08-12 |
Not clear |
| Philip D Harvey, Herbert Meltzer, George M Simpson, Steven G Potkin, Antony Loebel, Cynthia Siu, Steven J Roman. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia research. vol 66. issue 2-3. 2004-05-04. PMID:15061242. |
to assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n = 108), olanzapine (n = 104), or risperidone (n = 58) because of suboptimal efficacy or poor tolerability. |
2004-05-04 |
2023-08-12 |
Not clear |
| S M Stahl, M M Grad. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current medicinal chemistry. vol 11. issue 3. 2004-04-20. PMID:14965234. |
the atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms. |
2004-04-20 |
2023-08-12 |
Not clear |
| Nadeem H Bhanji, Guy Chouinard, Howard C Margoles. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 14. issue 2. 2004-04-19. PMID:15013023. |
a review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. |
2004-04-19 |
2023-08-12 |
Not clear |
| Takashi Togo, Eizo Iseki, Mika Shoji, Ikuo Oyama, Akihiko Kase, Hirotake Uchikado, Omi Katsuse, Kenji Kosak. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. Journal of pharmacological sciences. vol 91. issue 3. 2004-04-13. PMID:12686750. |
serum prolactin levels were investigated in 41 patients with schizophrenia who were receiving clinically effective doses of perospirone or risperidone for more than 4 weeks. |
2004-04-13 |
2023-08-12 |
Not clear |
| Zhongyun Zhao, Madhav Namjoshi, Beth L Barber, Danielle L Loosbrock, Sandra L Tunis, Baojin Zhu, Alan Breie. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS drugs. vol 18. issue 3. 2004-04-09. PMID:14871159. |
economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large us claims database. |
2004-04-09 |
2023-08-12 |
Not clear |
| Zhongyun Zhao, Madhav Namjoshi, Beth L Barber, Danielle L Loosbrock, Sandra L Tunis, Baojin Zhu, Alan Breie. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS drugs. vol 18. issue 3. 2004-04-09. PMID:14871159. |
to assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. |
2004-04-09 |
2023-08-12 |
Not clear |
| Alan S Bellack, Nina R Schooler, Stephen R Marder, John M Kane, Clayton H Brown, Ye Yan. Do clozapine and risperidone affect social competence and problem solving? The American journal of psychiatry. vol 161. issue 2. 2004-04-01. PMID:14754789. |
the purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia. |
2004-04-01 |
2023-08-12 |
Not clear |
| Carol J Lane, Elton T C Ngan, Lakshmi N Yatham, Tom J Ruth, Peter F Liddl. Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. Journal of psychiatry & neuroscience : JPN. vol 29. issue 1. 2004-03-25. PMID:14719048. |
immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. |
2004-03-25 |
2023-08-12 |
human |
| Carol J Lane, Elton T C Ngan, Lakshmi N Yatham, Tom J Ruth, Peter F Liddl. Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. Journal of psychiatry & neuroscience : JPN. vol 29. issue 1. 2004-03-25. PMID:14719048. |
to test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia. |
2004-03-25 |
2023-08-12 |
human |
| B K Puri, N J Davey, R Zama. Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports. International journal of clinical practice. vol 57. issue 9. 2004-03-22. PMID:14686575. |
we used transcranial magnetic stimulation-based techniques to study the time course of drug action in two antipsychotic drug-naive patients with schizophrenia; one patient treated with a typical antipsychotic (haloperidol) and the other with an atypical antipsychotic (risperidone). |
2004-03-22 |
2023-08-12 |
human |
| Tracy Swainston Harrison, Karen L Go. Long-acting risperidone: a review of its use in schizophrenia. CNS drugs. vol 18. issue 2. 2004-03-22. PMID:14728058. |
long-acting risperidone: a review of its use in schizophrenia. |
2004-03-22 |
2023-08-12 |
Not clear |
| Tracy Swainston Harrison, Karen L Go. Long-acting risperidone: a review of its use in schizophrenia. CNS drugs. vol 18. issue 2. 2004-03-22. PMID:14728058. |
elimination is complete 7-8 weeks after the last injection.long-acting risperidone 25 or 50mg every 2 weeks demonstrated significantly greater antipsychotic efficacy than placebo and equivalent efficacy to oral risperidone 2-6 mg/day in two randomised, double-blind, double-dummy, 12-week trials of patients with schizophrenia. |
2004-03-22 |
2023-08-12 |
Not clear |
| Tracy Swainston Harrison, Karen L Go. Long-acting risperidone: a review of its use in schizophrenia. CNS drugs. vol 18. issue 2. 2004-03-22. PMID:14728058. |
compared with baseline, improvements in the symptoms of schizophrenia in stable patients were significant with long-acting risperidone 25 or 50mg (12-month trial) and 25, 37.5 or 50mg (12-week trial) every 2 weeks, in two noncomparative, multicentre trials. |
2004-03-22 |
2023-08-12 |
Not clear |
| Gordon G Liu, Shawn X Sun, Dale B Christensen, Xuemei Lu. Cost comparisons of olanzapine and risperidone in treating schizophrenia. The Annals of pharmacotherapy. vol 38. issue 1. 2004-03-15. PMID:14742807. |
cost comparisons of olanzapine and risperidone in treating schizophrenia. |
2004-03-15 |
2023-08-12 |
Not clear |
| Gordon G Liu, Shawn X Sun, Dale B Christensen, Xuemei Lu. Cost comparisons of olanzapine and risperidone in treating schizophrenia. The Annals of pharmacotherapy. vol 38. issue 1. 2004-03-15. PMID:14742807. |
to review the literature on the healthcare costs associated with olanzapine and risperidone in treating schizophrenia. |
2004-03-15 |
2023-08-12 |
Not clear |
| Dilip V Jeste, Yoram Barak, Subramoniam Madhusoodanan, Fred Grossman, Georges Gharabaw. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 11. issue 6. 2004-03-12. PMID:14609804. |
international multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. |
2004-03-12 |
2023-08-12 |
Not clear |
| Dilip V Jeste, Yoram Barak, Subramoniam Madhusoodanan, Fred Grossman, Georges Gharabaw. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 11. issue 6. 2004-03-12. PMID:14609804. |
the authors compared the effects of the two most commonly used atypical antipsychotics, risperidone and olanzapine, in elderly patients with schizophrenia. |
2004-03-12 |
2023-08-12 |
Not clear |
| P Joseph Gibson, Robert Damler, E Anne Jackson, Teresa Wilder, Janet L Ramse. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 7. issue 1. 2004-03-11. PMID:14720128. |
the impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. |
2004-03-11 |
2023-08-12 |
Not clear |